Fragile X syndrome: A review of clinical management

Reymundo Lozano, Atoosa Azarang, Tanaporn Wilaisakditipakorn, Randi J Hagerman

Research output: Contribution to journalReview article

23 Citations (Scopus)

Abstract

The fragile X mental retardation 1 gene, which codes for the fragile X mental retardation 1 protein, usually has 5 to 40 CGG repeats in the 5' untranslated promoter. The full mutation is the almost always the cause of fragile X syndrome (FXS). The prevalence of FXS is about 1 in 4,000 to 1 in 7,000 in the general population although the prevalence varies in different regions of the world. FXS is the most common inherited cause of intellectual disability and autism. The understanding of the neurobiology of FXS has led to many targeted treatments, but none have cured this disorder. The treatment of the medical problems and associated behaviors remain the most useful intervention for children with FXS. In this review, we focus on the non-pharmacological and pharmacological management of medical and behavioral problems associated with FXS as well as current recommendations for follow-up and surveillance.

Original languageEnglish (US)
Pages (from-to)145-157
Number of pages13
JournalIntractable and Rare Diseases Research
Volume5
Issue number3
DOIs
StatePublished - 2016

Fingerprint

Fragile X Syndrome
Intellectual Disability
Fragile X Mental Retardation Protein
Neurobiology
Autistic Disorder
Pharmacology
Mutation
Therapeutics
Population
Genes

Keywords

  • Autism Spectrum Disorder
  • Clinical guidelines
  • Clinical management
  • Developmental delay
  • FMR1
  • FMRP
  • Fragile X syndrome
  • Intellectual Disability
  • Medical problems
  • Premutation
  • Treatment

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Fragile X syndrome : A review of clinical management. / Lozano, Reymundo; Azarang, Atoosa; Wilaisakditipakorn, Tanaporn; Hagerman, Randi J.

In: Intractable and Rare Diseases Research, Vol. 5, No. 3, 2016, p. 145-157.

Research output: Contribution to journalReview article

Lozano, Reymundo ; Azarang, Atoosa ; Wilaisakditipakorn, Tanaporn ; Hagerman, Randi J. / Fragile X syndrome : A review of clinical management. In: Intractable and Rare Diseases Research. 2016 ; Vol. 5, No. 3. pp. 145-157.
@article{ce1a09746b6f4d968342d877dc317fb3,
title = "Fragile X syndrome: A review of clinical management",
abstract = "The fragile X mental retardation 1 gene, which codes for the fragile X mental retardation 1 protein, usually has 5 to 40 CGG repeats in the 5' untranslated promoter. The full mutation is the almost always the cause of fragile X syndrome (FXS). The prevalence of FXS is about 1 in 4,000 to 1 in 7,000 in the general population although the prevalence varies in different regions of the world. FXS is the most common inherited cause of intellectual disability and autism. The understanding of the neurobiology of FXS has led to many targeted treatments, but none have cured this disorder. The treatment of the medical problems and associated behaviors remain the most useful intervention for children with FXS. In this review, we focus on the non-pharmacological and pharmacological management of medical and behavioral problems associated with FXS as well as current recommendations for follow-up and surveillance.",
keywords = "Autism Spectrum Disorder, Clinical guidelines, Clinical management, Developmental delay, FMR1, FMRP, Fragile X syndrome, Intellectual Disability, Medical problems, Premutation, Treatment",
author = "Reymundo Lozano and Atoosa Azarang and Tanaporn Wilaisakditipakorn and Hagerman, {Randi J}",
year = "2016",
doi = "10.5582/irdr.2016.01048",
language = "English (US)",
volume = "5",
pages = "145--157",
journal = "Intractable and Rare Diseases Research",
issn = "2186-3644",
publisher = "International Advancement Center for Medicine & Health Research Co., Ltd. (IACMHR Co., Ltd.)",
number = "3",

}

TY - JOUR

T1 - Fragile X syndrome

T2 - A review of clinical management

AU - Lozano, Reymundo

AU - Azarang, Atoosa

AU - Wilaisakditipakorn, Tanaporn

AU - Hagerman, Randi J

PY - 2016

Y1 - 2016

N2 - The fragile X mental retardation 1 gene, which codes for the fragile X mental retardation 1 protein, usually has 5 to 40 CGG repeats in the 5' untranslated promoter. The full mutation is the almost always the cause of fragile X syndrome (FXS). The prevalence of FXS is about 1 in 4,000 to 1 in 7,000 in the general population although the prevalence varies in different regions of the world. FXS is the most common inherited cause of intellectual disability and autism. The understanding of the neurobiology of FXS has led to many targeted treatments, but none have cured this disorder. The treatment of the medical problems and associated behaviors remain the most useful intervention for children with FXS. In this review, we focus on the non-pharmacological and pharmacological management of medical and behavioral problems associated with FXS as well as current recommendations for follow-up and surveillance.

AB - The fragile X mental retardation 1 gene, which codes for the fragile X mental retardation 1 protein, usually has 5 to 40 CGG repeats in the 5' untranslated promoter. The full mutation is the almost always the cause of fragile X syndrome (FXS). The prevalence of FXS is about 1 in 4,000 to 1 in 7,000 in the general population although the prevalence varies in different regions of the world. FXS is the most common inherited cause of intellectual disability and autism. The understanding of the neurobiology of FXS has led to many targeted treatments, but none have cured this disorder. The treatment of the medical problems and associated behaviors remain the most useful intervention for children with FXS. In this review, we focus on the non-pharmacological and pharmacological management of medical and behavioral problems associated with FXS as well as current recommendations for follow-up and surveillance.

KW - Autism Spectrum Disorder

KW - Clinical guidelines

KW - Clinical management

KW - Developmental delay

KW - FMR1

KW - FMRP

KW - Fragile X syndrome

KW - Intellectual Disability

KW - Medical problems

KW - Premutation

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85020574873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020574873&partnerID=8YFLogxK

U2 - 10.5582/irdr.2016.01048

DO - 10.5582/irdr.2016.01048

M3 - Review article

AN - SCOPUS:85020574873

VL - 5

SP - 145

EP - 157

JO - Intractable and Rare Diseases Research

JF - Intractable and Rare Diseases Research

SN - 2186-3644

IS - 3

ER -